Biocom
Based in CA
AI Overview
With $2.1M in lobbying spend across 34 quarterly filings, Biocom is a significant lobbying presence. Their lobbying covers 11 issue areas. Active from 2018 to 2025.
Spending Trend
View as table
| Year | Lobbying Spend |
|---|---|
| 2018 | $184K |
| 2019 | $213K |
| 2020 | $250K |
| 2021 | $180K |
| 2022 | $300K |
| 2023 | $300K |
| 2024 | $300K |
| 2025 | $375K |
Issues Lobbied
Lobbying Firms
Lobbyists
Government Agencies Targeted
These are the government entities that Biocom disclosed contacting in their lobbying filings.
What They Lobby About
These are actual descriptions from their quarterly lobbying disclosure filings, summarizing what they lobbied Congress and federal agencies about.Issue areas: Health Issues, Budget/Appropriations, Taxation, Copyright/Patent, Energy and 6 more
Hosted an advocacy fly-in about regenerative medicine
Discussed how the life science community can help address the opioid crisis
Supported expanded coverage of whole-genome sequencing
Advocated for
Advocated for increased funding for NIH and FDA in FY2018 omnibus.
Advocated for the suspension of the medical device tax.
Advocated for reforms of IPR proceedings at the PTAB, including support of the STRONGER Patents Act
Advocated for increased funding for NIH and FDA in FY2019 appropriations.
Related Analysis
Related Investigations
Similar Clients
Explore More
Data Sources: Senate LDA Filings
Last updated: February 2026
This site is an independent journalism project. Analysis and editorial content are not affiliated with or endorsed by any government agency.